Compare BLNK & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | PLRX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.9M | 81.1M |
| IPO Year | 2008 | 2020 |
| Metric | BLNK | PLRX |
|---|---|---|
| Price | $0.71 | $1.20 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | $2.33 | ★ $2.67 |
| AVG Volume (30 Days) | ★ 2.0M | 546.0K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.22 | 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $126,197,000.00 | N/A |
| Revenue This Year | $5.71 | N/A |
| Revenue Next Year | $19.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $1.09 |
| 52 Week High | $2.65 | $1.95 |
| Indicator | BLNK | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 38.23 |
| Support Level | $0.63 | $1.13 |
| Resistance Level | $0.73 | $1.37 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 49.75 | 18.18 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.